Search clinical trials for: Irbesartan/Amlodipine FDC

Total 3677 results

Sanofi

Completed

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Hypertension

Russian Federation
Handok Inc.

Completed

Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Sanofi

Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure (I-COMBO)

Hypertension

India, Philippines, Taiwan, Korea, Republic of
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (I-ADD)

Hypertension

Morocco, Brazil, Colombia, Guatemala, Mexico, Tunisia, United Arab Emirates, Venezuela
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy (I-COMBINE)

Hypertension

Brazil, Chile, Colombia, Egypt, Lebanon, Mexico, Morocco, Tunisia, Venezuela
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Handok Inc.

Completed

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Essential Hypertension

Korea, Republic of
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
GlaxoSmithKline

Completed

Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions

Hypertension

South Africa
Assistance Publique - Hôpitaux de Paris

Completed

PHARES Study: Management of Resistant Hypertension

Hypertension

France
Radboud University Medical Center

Completed

Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Prostatic Neoplasms | Immunotherapy | Vaccines | Dendritic Cells

Netherlands
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Healthy

Japan
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use

Healthy

Japan
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Therapeutic Equivalency

China
GlaxoSmithKline
SingHealth Investigational Medicine Unit, Singapore

Completed

Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions

Hypertension

Singapore
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Healthy
Chong Kun Dang Pharmaceutical
Severance Hospital

Completed

Drug-drug Interaction Study(CKD-501, Amlodipine)

Type 2 Diabetes Mellitus

Korea, Republic of
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Hypertension

United States, Belgium, Canada, Germany, Russian Federation, France, Israel, Netherlands
LanZhou University

Unknown

Combined Antihypertensive Therapy and Sexual Dysfunction

Hypertension | Sexual Dysfunction

China
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Healthy
Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
Zhi-Hong Liu, M.D.

Terminated

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Obesity and Glomerulopathy

China
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Damanhour University

Completed

Drug Interaction Between Irbesartan and Hydrochlorothiazide

Healthy

Egypt
University of Southern Denmark
Bristol-Myers Squibb

Completed

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Myocardial Infarction

Denmark
Sanofi
Bristol-Myers Squibb

Completed

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Hypertension

Egypt
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Diabetic Kidney Disease

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Sanofi
Bristol-Myers Squibb

Completed

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Hypertension

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Hypertension

Egypt
Ligand Pharmaceuticals

Completed

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Hypertension

United States
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Shandong Suncadia Medicine Co., Ltd.

Completed

A HR20031 FE Study on Healthy Subjects

Type 2 Diabetes

China
Shandong Suncadia Medicine Co., Ltd.

Active, not recruiting

A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers

Type II Diabetes

China
Sanofi

Completed

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Hypertension

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Hypertension

United States, Canada, Germany, Russian Federation, France
University of Oklahoma
VA Office of Research and Development

Terminated

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

Brain Ischemia | Brain Infarction

United States
Novartis

Completed

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Hypertension

Switzerland, Germany
Sanofi
Bristol-Myers Squibb

Completed

AMISH : Aprovel for Management of Isolated Systolic Hypertension

Hypertension

Korea, Republic of, Mexico, Taiwan, Thailand, Philippines, Chile, China, Indonesia
Daewoong Pharmaceutical Co. LTD.

Completed

Clinical Trial to Investigate the Efficacy and Safety of DWJ1351

Healthy

Korea, Republic of

3

Subscribe